The role of protons in modern and biologically-guided radiotherapy

被引:14
|
作者
Nystrom, Hakan [1 ,2 ]
机构
[1] Skandion Clin, S-75136 Uppsala, Sweden
[2] Univ Copenhagen, Niels Bohr Inst, DK-2100 Copenhagen, Denmark
关键词
CELL LUNG-CANCER; TUMOR-CONTROL PROBABILITY; NORMAL TISSUE; CONCURRENT CHEMOTHERAPY; INDUCTION CHEMOTHERAPY; IMRT TREATMENT; PHASE-II; RISK; DISTRIBUTIONS; OPTIMIZATION;
D O I
10.3109/0284186X.2010.498436
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
With the introduction of new biologically based imaging possibilities, a higher degree of individualisation and adaptation of radiotherapy will be possible. Better knowledge of the biology of the target and its sub-volumes will enable dose prescriptions tailored to the individual patients, tissues and sub-volumes. Repeated imaging during the course of treatment will in addition enable adaptation of the treatment to cope with anatomical, as well as biological changes of the patient and of the target tissues. To translate these bright future perspectives into significant improvements in clinical outcome, advanced tools to tailor the physical dose distributions are needed. The most conformal radiotherapy technique known to mankind and clinically available today is proton therapy; in particular Intensity Modulated Proton Therapy (IMPT) with active spot scanning can not only tailor the dose to the desired target, but also effectively avoid sensitive structures in the proximity of the target to a degree far better than other conformal techniques such as Intensity Modulated Radiotherapy with photons (IMRT). The development of IMPT is now mature enough for clinical introduction on a broad scale. Proton therapy is still more expensive than conventional radiotherapy, but with the present rapid increase in the number of proton facilities worldwide and new initiatives to improve efficiency, the difference in affordability will continue to decrease and in comparison with the benefits, soon diminish even further. Contrary to what is sometimes claimed, the demands for better physical dose distributions and better avoidance of non-target tissue, has never been higher. Prolonged expected survival in many groups of patients emphasises the need to reduce late toxicities. The success of concomitant systemic therapies, with their tendency to cause higher morbidity stresses even further the increased need for subtle dose-sculpting methodologies and tools. There is no contradiction between striving for better physical dose distributions and a more biologically based approach. On the contrary, physical dose distributions are the tools to which achieve a treatment that can meet the biological demands.
引用
收藏
页码:1124 / 1131
页数:8
相关论文
共 50 条
  • [11] Biologically-Guided Multi-Criteria Optimization and Exploration to Generate Clinical Plans for Functionality-Sparing Radiation Therapy Trials
    Kim, M.
    Wang, J. Y.
    Kidd, E.
    Hristov, D.
    MEDICAL PHYSICS, 2024, 51 (10) : 7793 - 7794
  • [12] Biologically-Guided Isolation of Natural Lead Antithyroid Drug from Medicago sativa L. Sprouts and Its Toxic Profile in Comparison with Propylthiouracil
    Ibrahim, Reham S.
    El-Mezayen, Nesrine S.
    Khairy, Asmaa
    Zaatout, Hala H.
    Hammoda, Hala M.
    Metwally, Aly M.
    JOURNAL OF FOOD AND DRUG ANALYSIS, 2020, 28 (03) : 407 - 448
  • [13] The role of radiotherapy in modern melanoma treatment
    Bastholt, L.
    Bahij, R.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S79 - S79
  • [14] The role of in vivo dosimetry in modern radiotherapy
    Bulski, W
    Rostkowska, J
    Kania, M
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S358 - S358
  • [15] THE ROLE OF IN VIVO DOSIMETRY IN MODERN RADIOTHERAPY
    Bulski, W.
    Rostkowska, J.
    Kania, M.
    Walewska, A.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S401 - S401
  • [16] Biology-guided radiotherapy: redefining the role of radiotherapy in metastatic cancer
    Shirvani, Shervin M.
    Huntzinger, Calvin J.
    Melcher, Thorsten
    Olcott, Peter D.
    Voronenko, Yevgen
    Bartlett-Roberto, Judy
    Mazin, Samuel
    BRITISH JOURNAL OF RADIOLOGY, 2021, 94 (1117):
  • [17] Do protons have a role in the treatment of locally advanced NSCLC with radiotherapy?
    McDonald, Fiona
    Hanna, Gerard G.
    LUNG CANCER, 2017, 110 : 71 - 73
  • [18] On the potential role of protons in radiotherapy of skull base chordoma in a young patient
    Kadiri, L.
    Rogers, J.
    Green, S.
    Jones, B.
    Hoole, A. F. C.
    Chantter, H.
    Burnet, N. G.
    CLINICAL ONCOLOGY, 2007, 19 (03) : S35 - S35
  • [19] Modern PET-Guided Radiotherapy Planning and Treatment for Malignant Lymphoma
    Pepper, Niklas Benedikt
    Oertel, Michael
    Rehn, Stephan
    Kobe, Carsten
    Eich, Hans Theodor
    SEMINARS IN NUCLEAR MEDICINE, 2023, 53 (03) : 389 - 399
  • [20] First Beam Commissioning Report of a Novel Medical Linear Accelerator Designed for Biologically Guided Radiotherapy
    Han, B.
    Kovalchuk, N.
    Capaldi, D. P.
    Simiele, E.
    White, J.
    Purwar, A.
    Yeung, T.
    Maganti, S.
    Mitra, A.
    Voronenko, Y.
    Oderinde, O. M.
    Shirvani, S. M.
    Kuduvalli, G.
    Vitzthum, L.
    Chang, D. T.
    Xing, L.
    Surucu, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E512 - E512